2003
Vascular Endothelial Growth Factor Expression, β-Catenin Tyrosine Phosphorylation, and Endothelial Proliferative Behavior: A Pathway for Transformation?
Ilan N, Tucker A, Madri JA. Vascular Endothelial Growth Factor Expression, β-Catenin Tyrosine Phosphorylation, and Endothelial Proliferative Behavior: A Pathway for Transformation? Laboratory Investigation 2003, 83: 1105-1115. PMID: 12920240, DOI: 10.1097/01.lab.0000083531.84403.8b.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, BlockingAntigens, CD1Beta CateninCell DivisionCell Transformation, NeoplasticCytoskeletal ProteinsEndothelial Growth FactorsEndothelium, VascularExtracellular Matrix ProteinsHemangioendotheliomaHumansIntercellular Signaling Peptides and ProteinsLymphokinesPhosphorylationTrans-ActivatorsTumor Cells, CulturedTyrosineUmbilical VeinsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth FactorsConceptsVascular endothelial growth factorEOMA cellsCD1 levelsFlk-1Vascular endothelial growth factor (VEGF) expressionExogenous vascular endothelial growth factorEndogenous vascular endothelial growth factorEndothelial cell tumorsGrowth factor expressionEndothelial growth factorTyrosine phosphorylationNuclear beta-catenin localizationNuclear localizationProliferative behaviorΒ-catenin tyrosine phosphorylationHuman endothelial cellsComponent expression levelsCD1 expressionCell tumorsCommon tumorsImmune complex kinase assayEndothelial cell transformationMitogen-activated protein kinase activationPrimary human endothelial cellsAutocrine loop
1996
Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.
Wang Y, Hu Q, Madri J, Rollins S, Chodera A, Matis L. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proceedings Of The National Academy Of Sciences Of The United States Of America 1996, 93: 8563-8568. PMID: 8710910, PMCID: PMC38712, DOI: 10.1073/pnas.93.16.8563.Peer-Reviewed Original ResearchConceptsNZB/W F1 miceNZB/WF1 miceLupus-like autoimmune diseaseW F1 miceF1 miceAutoimmune diseasesNew Zealand Black x New Zealand White F1 miceFemale NZB/W F1 miceFemale NZB/WF1 miceHuman systemic lupus erythematosusMonoclonal antibodiesCourse of glomerulonephritisSystemic lupus erythematosusImmune complex glomerulonephritisSystemic complement activationWhite F1 miceImmune complex nephritisMonths of ageSevere glomerulonephritisAntinuclear antibodiesComplement component C5Continuous therapyAutoimmune syndromeLupus erythematosusRenal disease